Acute On Chronic Liver Failure (ACLF) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Acute On Chronic Liver Failure (ACLF) – Drugs In Development, 2024 report and make more profitable business decisions.
Acute-on-chronic liver failure occurs in patients with chronic liver disease and is characterized by acute deterioration of the patient requiring hospitalization and is associated with (1) hepatic and extrahepatic organ dysfunction, (2) systemic inflammation, and (3) a high 28-day mortality rate.
The Acute On Chronic Liver Failure (ACLF) drugs in development market research report provide comprehensive information on the therapeutics under development for Acute On Chronic Liver Failure (ACLF), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute On Chronic Liver Failure (ACLF) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Acute On Chronic Liver Failure (ACLF) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 15 molecules, with 14 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Acute On Chronic Liver Failure (ACLF) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Acute On Chronic Liver Failure (ACLF) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Acute On Chronic Liver Failure (ACLF) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Akaza Bioscience LtdCellaion SA
Genfit SA
GNI Group Ltd
Guangzhou Saijun Biological Technology Co Ltd
Huaxia Source Cell Engineering Group Co Ltd
Mitopower LLC
Shanghai Hexaell Biotech Co Ltd
Shenzhen Wingor Biotechnology Co Ltd
Sun Yat-sen University
Tianjin Angsai Cell Genetic Engineering Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Acute Liver Failure reports